Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

NCT04830449 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1904-2
DRUG: RLD2001-2

Sponsor

Hanmi Pharmaceutical Company Limited